BioCryst Pharmaceuticals raised its full-year 2026 revenue guidance to US$715 million to US$730 million and reported third quarter 2026 revenue of US$180.29 million and net income of US$37.92 million,...
Source LinkBioCryst Pharmaceuticals raised its full-year 2026 revenue guidance to US$715 million to US$730 million and reported third quarter 2026 revenue of US$180.29 million and net income of US$37.92 million,...
Source Link
Comments